Intranasal Foralumab for Multiple Sclerosis Now Approved by FDA for At-Home Dosing
October 20, 2023 Isabella Ciccone, M.P.H. The FDA’s decision to allow at-home dosing of intransal foralumab for patients with multiple…
S1P Receptor Modulator May Boost Cognitive Processing Speed in Early MS
Ozanimod (Zeposia) led to test score improvements in interim analysis by Judy George, Deputy Managing Editor, MedPage Today October 19, 2023 Share…
Stuart Schlossman
BTK Inhibitor Reduces Brain Lesions in Relapsing MS
— Subgroup analysis shows brain penetration by Judy George, Deputy Managing Editor, MedPage Today October 19, 2023 Share on Facebook. Opens…
Stuart Schlossman
PRESS RELEASE: Genentech’s Ocrevus Twice-Yearly, 10-Minute Subcutaneous Injection Was Non-Inferior to Intravenous Infusion and Provided Near-Complete Suppression of Brain Lesions
Late-breaking Phase III results show subcutaneous injection was non-inferior to intravenous infusion based on Ocrevus levels in the blood over…
Stuart Schlossman
First-Ever Clinical Trial Exclusively in Black and Hispanic / Latinx People Living With Multiple Sclerosis Shows Genentech’s Ocrevus Effectively Manages Disease Activity
October 10, 2023 Black and Hispanic / Latinx people with multiple sclerosis (MS) often experience more severe disease and greater…
Stuart Schlossman
How to give Ocrelizumab…Differently?! – presented by Aaron Boster, MD
Stay informed with MS information, news and resources. Sign-up Here: https://bit.ly/3NkMIeR Visit the MS Views and News articles and videos…
Stuart Schlossman
ECTRIMS: Sanofi to Present New Data for Tolebrutinib and Growing MS Pipeline
Media Update: Sanofi presents new data from robust MS clinical pipeline exploring multiple approaches to address important unmet patient needs…
Stuart Schlossman
Genentech to Present New Key Clinical and Real-world Data at ECTRIMS-ACTRIMS 2023 Showcasing Strength of Long-term Outcomes in MS and NMOSD
Late-breaking results from Phase III trial of Ocrevus (ocrelizumab) subcutaneous injection and Phase II trial of BTK inhibitor fenebrutinib in…
Stuart Schlossman
Generic and Biosimilar Medications for MS
Generics and biosimilars are follow-on medications. A generic is a follow-on medication to a brand medication and a biosimilar is…
Stuart Schlossman
FDA Approves First Biosimilar to Treat Multiple Sclerosis
For Immediate Release: August 24, 2023 The U.S. Food and Drug Administration today approved Tyruko (natalizumab-sztn), the first biosimilar to Tysabri (natalizumab)…
Stuart Schlossman
